United States Biotechnology & Medical Research

Alpine Immune Sciences Inc (ALPN)

Track

Ticker: ALPN Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Alpine Immune Sciences Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 25 Apr 2024
Value US$3,549,030.86 | Price 423.28 | Shares 47,489 (+38.9%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2024-04-29 2024-04-25 S Sale
3.7
Topper James N
Non-Executive Director
47,489 +38.9%
423.28
US$3,549,031 		47,489 +38.9% 423.28 US$3,549,031
2024-01-29 2024-01-26 PlS Planned sale
3.3
Rickey James Paul

See Remarks

Officer
88,518 +28.1%
304.48
US$3,893,459 		88,518 +28.1% 304.48 US$3,893,459
2024-01-29 2024-01-26 PlS Planned sale
3.3
Rickey James Paul

See Remarks

Officer
46,018 -12.6%
442.84
US$275,549 		46,018 -12.6% 442.84 US$275,549
2024-01-26 2024-01-26 PrS Proposed sale
3.3
JAMES PAUL RICKEY

Officer

Officer
44,000
21.74
US$956,560 		44,000 21.74 US$956,560
2024-01-29 2024-01-25 PlS Planned sale
3.3
Rickey James Paul

See Remarks

Officer
236 -100.0%
22.00
US$5,192 		236 -100.0% 22.00 US$5,192
2024-01-25 2024-01-25 PrS Proposed sale
3.3
JAMES PAUL RICKEY

Officer

Officer
74,000
18.56
US$1,373,440 		74,000 18.56 US$1,373,440
2023-12-29 2023-12-28 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
139,166 -34.5%
18.32
US$2,549,521 		139,166 -34.5% 18.32 US$2,549,521
2023-12-29 2023-12-28 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
1,195,683 -34.5%
18.32
US$21,904,913 		1,195,683 -34.5% 18.32 US$21,904,913
2023-12-29 2023-12-28 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
3,128 -0.8%
19.82
US$61,997 		3,128 -0.8% 19.82 US$61,997
2023-12-29 2023-12-28 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
26,872 -0.8%
19.82
US$532,603 		26,872 -0.8% 19.82 US$532,603
2023-12-29 2023-12-28 PlS Planned sale
3.1
GOLD MITCHELL

Executive Chairman and CEO

Executive Director
1,016 -100.0%
20.04
US$20,362 		1,016 -100.0% 20.04 US$20,362
2023-12-29 2023-12-28 S Sale
3.0
Thompson Peter A.
Non-Executive Director
139,166 -34.5%
18.32
US$2,549,521 		139,166 -34.5% 18.32 US$2,549,521
2023-12-29 2023-12-28 S Sale
3.0
Thompson Peter A.
Non-Executive Director
1,195,683 -34.5%
18.32
US$21,904,913 		1,195,683 -34.5% 18.32 US$21,904,913
2023-12-29 2023-12-28 S Sale
3.0
Thompson Peter A.
Non-Executive Director
3,128 -0.8%
19.82
US$61,997 		3,128 -0.8% 19.82 US$61,997
2023-12-29 2023-12-28 S Sale
3.0
Thompson Peter A.
Non-Executive Director
26,872 -0.8%
19.82
US$532,603 		26,872 -0.8% 19.82 US$532,603
2023-12-29 2023-12-27 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
18,922 -4.4%
19.96
US$377,683 		18,922 -4.4% 19.96 US$377,683
2023-12-29 2023-12-27 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
162,576 -4.4%
19.96
US$3,245,017 		162,576 -4.4% 19.96 US$3,245,017
2023-12-29 2023-12-27 S Sale
3.0
Thompson Peter A.
Non-Executive Director
18,922 -4.4%
19.96
US$377,683 		18,922 -4.4% 19.96 US$377,683
2023-12-29 2023-12-27 S Sale
3.0
Thompson Peter A.
Non-Executive Director
162,576 -4.4%
19.96
US$3,245,017 		162,576 -4.4% 19.96 US$3,245,017
2023-12-27 2023-12-27 PrS Proposed sale
2.6
OrbiMed Private Investments VI, LP

Shareholder
1,385,131
20.22
US$28,007,349 		1,385,131 20.22 US$28,007,349
2023-12-27 2023-12-27 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, L.P.

Shareholder
161,216
20.22
US$3,259,788 		161,216 20.22 US$3,259,788
2023-12-27 2023-12-27 PlS Planned sale
3.1
GOLD MITCHELL

Executive Chairman and CEO

Executive Director
29,573 -100.0%
20.04
US$592,717 		29,573 -100.0% 20.04 US$592,717
2023-12-27 2023-12-26 PlS Planned sale
3.1
GOLD MITCHELL

Executive Chairman and CEO

Executive Director
24,486 -100.0%
20.22
US$495,217 		24,486 -100.0% 20.22 US$495,217
2023-12-27 2023-12-22 PlS Planned sale
3.1
GOLD MITCHELL

Executive Chairman and CEO

Executive Director
37,825 -100.0%
20.43
US$772,595 		37,825 -100.0% 20.43 US$772,595
2023-12-21 2023-12-19 PlS Planned sale
3.3
Rickey James Paul

See Remarks

Officer
15,213 -100.0%
19.21
US$292,222 		15,213 -100.0% 19.21 US$292,222
2023-12-21 2023-12-19 PlS Planned sale
3.1
GOLD MITCHELL

Executive Chairman and CEO

Executive Director
2,402 -100.0%
20.01
US$48,064 		2,402 -100.0% 20.01 US$48,064
2023-12-19 2023-12-19 PrS Proposed sale
3.1
Mitchell H. Gold

Officer

Officer
120,000
20.00
US$2,400,000 		120,000 20.00 US$2,400,000
2023-12-18 2023-12-18 PlS Planned sale
3.3
Rickey James Paul

See Remarks

Officer
1,800 -100.0%
19.00
US$34,203 		1,800 -100.0% 19.00 US$34,203
2023-12-18 2023-12-15 PlS Planned sale
3.3
Rickey James Paul

See Remarks

Officer
45,387 -100.0%
19.09
US$866,383 		45,387 -100.0% 19.09 US$866,383
2023-12-15 2023-12-15 PrS Proposed sale
3.3
JAMES PAUL RICKEY

Officer

Officer
62,400
18.88
US$1,178,112 		62,400 18.88 US$1,178,112
2023-12-18 2023-12-14 PlS Planned sale
3.3
Rickey James Paul

See Remarks

Officer
11,600 -100.0%
19.00
US$220,406 		11,600 -100.0% 19.00 US$220,406
2023-12-14 2023-12-14 PrS Proposed sale
3.3
JAMES PAUL RICKEY

Officer

Officer
11,600
18.81
US$218,196 		11,600 18.81 US$218,196
2023-12-12 2023-12-12 PlS Planned sale
3.1
GOLD MITCHELL

Executive Chairman and CEO

Executive Director
8,613 -100.0%
17.32
US$149,138 		8,613 -100.0% 17.32 US$149,138
2023-12-12 2023-12-12 PlS Planned sale
3.1
GOLD MITCHELL

Executive Chairman and CEO

Executive Director
32,450 -100.0%
17.32
US$561,888 		32,450 -100.0% 17.32 US$561,888
2023-12-12 2023-12-11 PlS Planned sale
3.1
GOLD MITCHELL

Executive Chairman and CEO

Executive Director
68,870 -68.0%
17.26
US$1,189,027 		68,870 -68.0% 17.26 US$1,189,027
2023-12-12 2023-12-08 PlS Planned sale
3.1
GOLD MITCHELL

Executive Chairman and CEO

Executive Director
8,067 -7.4%
17.08
US$137,784 		8,067 -7.4% 17.08 US$137,784
2023-12-08 2023-12-08 PrS Proposed sale
3.1
Mitchell H. Gold

Officer

Officer
118,000
16.84
US$1,987,120 		118,000 16.84 US$1,987,120
2023-12-06 2023-12-06 PlS Planned sale
3.3
Rickey James Paul

See Remarks

Officer
6,446 -100.0%
16.08
US$103,650 		6,446 -100.0% 16.08 US$103,650
2023-12-06 2023-12-05 PlS Planned sale
3.3
Rickey James Paul

See Remarks

Officer
418 -100.0%
16.01
US$6,694 		418 -100.0% 16.01 US$6,694
2023-12-06 2023-12-04 PlS Planned sale
3.3
Rickey James Paul

See Remarks

Officer
63,947 -100.0%
16.06
US$1,026,887 		63,947 -100.0% 16.06 US$1,026,887
2023-12-01 2023-11-30 PlS Planned sale
3.3
Rickey James Paul

See Remarks

Officer
700 -100.0%
16.00
US$11,200 		700 -100.0% 16.00 US$11,200
2023-11-14 2023-11-09 B Purchase
3.4
Decheng Capital Global Healthcare Fund (Master), LP
Large shareholder
375,000 +27.6%
12.50
US$4,687,500 		375,000 +27.6% 12.50 US$4,687,500
2023-11-14 2023-11-09 B Purchase
3.7
Cui Xiangmin
Non-Executive Director Large shareholder
375,000 +27.6%
12.50
US$4,687,500 		375,000 +27.6% 12.50 US$4,687,500
2023-11-08 2023-11-06 PlS Planned sale
3.3
Rickey James Paul

See Remarks

Officer
18,003 -100.0%
16.03
US$288,554 		18,003 -100.0% 16.03 US$288,554
2023-11-06 2023-11-06 PrS Proposed sale
3.3
JAMES PAUL RICKEY

Officer

Officer
89,514
16.07
US$1,438,490 		89,514 16.07 US$1,438,490
2022-02-15 2022-02-11 B Purchase
3.9
Frazier Life Sciences VIII, L.P.
Large shareholder
112,665 +8.2%
7.10
US$799,989 		112,665 +8.2% 7.10 US$799,989
2022-01-04 2021-12-31 S Sale
3.3
Rickey James Paul

Senior VP and CFO

Officer
17,013 -70.8%
13.92
US$236,756 		17,013 -70.8% 13.92 US$236,756
2021-09-17 2021-09-16 PlS Planned sale
3.1
GOLD MITCHELL

Executive Chairman and CEO

Executive Director Large shareholder
6,768 -4.2%
10.00
US$67,696 		6,768 -4.2% 10.00 US$67,696
2021-09-17 2021-09-15 PlS Planned sale
3.1
GOLD MITCHELL

Executive Chairman and CEO

Executive Director Large shareholder
3,484 -2.1%
10.00
US$34,840 		3,484 -2.1% 10.00 US$34,840
2021-06-29 2021-06-28 PlS Planned sale
3.1
GOLD MITCHELL

Executive Chairman and CEO

Executive Director Large shareholder
3,479 -2.1%
10.00
US$34,792 		3,479 -2.1% 10.00 US$34,792
2021-06-29 2021-06-25 PlS Planned sale
3.1
GOLD MITCHELL

Executive Chairman and CEO

Executive Director Large shareholder
9,473 -5.3%
10.01
US$94,865 		9,473 -5.3% 10.01 US$94,865
2021-03-08 2021-03-05 PlS Planned sale
3.1
GOLD MITCHELL

Executive Chairman and CEO

Executive Director Large shareholder
10,000 -3.6%
12.99
US$129,875 		10,000 -3.6% 12.99 US$129,875
2021-03-08 2021-03-04 PlS Planned sale
3.1
GOLD MITCHELL

Executive Chairman and CEO

Executive Director Large shareholder
10,000 -3.4%
13.01
US$130,108 		10,000 -3.4% 13.01 US$130,108
2021-02-03 2021-02-02 PlS Planned sale
3.1
GOLD MITCHELL

Executive Chairman and CEO

Executive Director Large shareholder
10,000 -3.3%
11.74
US$117,381 		10,000 -3.3% 11.74 US$117,381
2021-02-03 2021-02-01 PlS Planned sale
3.1
GOLD MITCHELL

Executive Chairman and CEO

Executive Director Large shareholder
7,021 -2.3%
13.20
US$92,698 		7,021 -2.3% 13.20 US$92,698
2021-02-03 2021-02-01 PlS Planned sale
3.1
GOLD MITCHELL

Executive Chairman and CEO

Executive Director Large shareholder
2,979 -1.0%
12.07
US$35,968 		2,979 -1.0% 12.07 US$35,968
2020-12-30 2020-12-28 S Sale
3.0
Thompson Peter A.
Non-Executive Director Large shareholder
600,000 -16.3%
14.25
US$8,550,000 		600,000 -16.3% 14.25 US$8,550,000
2020-12-30 2020-12-28 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
600,000 -16.3%
14.25
US$8,550,000 		600,000 -16.3% 14.25 US$8,550,000
2020-11-23 2020-11-19 B Purchase
3.3
CONWAY ROBERT E
Non-Executive Director
10,000 +66.7%
8.03
US$80,300 		10,000 +66.7% 8.03 US$80,300
2019-06-03 2019-05-30 B Purchase
3.3
Rickey James Paul

Senior VP and CFO
10,000 +inf%
4.95
US$49,500 		10,000 +inf% 4.95 US$49,500
2019-02-12 2019-02-08 S Sale
1.5
TIGER MANAGEMENT L.L.C.
Large shareholder
25,000 -15.4%
5.85
US$146,245 		25,000 -15.4% 5.85 US$146,245
2019-01-23 2019-01-18 B Purchase
3.0
Thompson Peter A.
Non-Executive Director Large shareholder
372,439 +11.3%
5.37
US$1,999,997 		372,439 +11.3% 5.37 US$1,999,997
2019-01-23 2019-01-18 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
372,439 +11.3%
5.37
US$1,999,997 		372,439 +11.3% 5.37 US$1,999,997
2019-01-22 2019-01-18 B Purchase
3.1
GOLD MITCHELL

Executive Chairman and CEO

Executive Director Large shareholder
190,875 +5.0%
5.37
US$1,024,999 		190,875 +5.0% 5.37 US$1,024,999
2019-01-22 2019-01-18 B Purchase
3.7
Topper James N
Non-Executive Director Large shareholder
372,439 +16.9%
5.37
US$1,999,997 		372,439 +16.9% 5.37 US$1,999,997
2019-01-22 2019-01-18 B Purchase
3.5
Venkatesan Jay
Non-Executive Director Large shareholder
190,875 +5.0%
5.37
US$1,024,999 		190,875 +5.0% 5.37 US$1,024,999
2019-01-22 2019-01-18 B Purchase
3.1
Alpine ImmunoSciences, L.P.
Large shareholder
190,875 +5.0%
5.37
US$1,024,999 		190,875 +5.0% 5.37 US$1,024,999
2019-01-22 2019-01-18 B Purchase
3.9
Frazier Life Sciences VIII, L.P.
Large shareholder
372,439 +16.9%
5.37
US$1,999,997 		372,439 +16.9% 5.37 US$1,999,997
2017-06-22 2017-06-20 B Purchase BVF PARTNERS L P/IL Large shareholder
1,715 +0.9%
2.25
US$3,859 		1,715 +0.9% 2.25 US$3,859
2017-06-22 2017-06-20 B Purchase BVF PARTNERS L P/IL Large shareholder
6,359 +0.9%
2.25
US$14,308 		6,359 +0.9% 2.25 US$14,308
2017-06-22 2017-06-20 B Purchase BVF PARTNERS L P/IL Large shareholder
9,732 +0.9%
2.25
US$21,897 		9,732 +0.9% 2.25 US$21,897
2017-06-07 2017-06-07 B Purchase BVF PARTNERS L P/IL Large shareholder
3,673 +1.9%
2.28
US$8,379 		3,673 +1.9% 2.28 US$8,379
2017-06-07 2017-06-07 B Purchase BVF PARTNERS L P/IL Large shareholder
13,046 +1.9%
2.28
US$29,762 		13,046 +1.9% 2.28 US$29,762
2017-06-07 2017-06-07 B Purchase BVF PARTNERS L P/IL Large shareholder
20,181 +1.9%
2.28
US$46,039 		20,181 +1.9% 2.28 US$46,039
2017-06-07 2017-06-05 B Purchase BVF PARTNERS L P/IL Large shareholder
3,920 +2.0%
2.29
US$8,979 		3,920 +2.0% 2.29 US$8,979
Explore more

More insider trading research around Alpine Immune Sciences Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America